Similar articles for PMID: 26383153

Year	Number of Results
2003	2
2004	5
2005	4
2006	6
2007	5
2008	6
2009	3
2010	5
2011	5
2012	6
2013	9
2014	12
2015	14
2016	14
2017	5
2018	3
2019	9
2020	8
2021	1
2023	1
2024	0

1

Multicenter Reproducibility of 18F-Fluciclatide PET Imaging in Subjects with Solid Tumors.

Sharma R, Kallur KG, Ryu JS, Parameswaran RV, Lindman H, Avril N, Gleeson FV, Lee JD, Lee KH, O'Doherty MJ, Groves AM, Miller MP, Somer EJ, Coombes CR, Aboagye EO. Sharma R, et al. J Nucl Med. 2015 Dec;56(12):1855-61. doi: 10.2967/jnumed.115.158253. Epub 2015 Sep 17. J Nucl Med. 2015. PMID: 26383153 Free article.

2

Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αVbeta3-integrin and αV beta5-integrin imaging agent.

Battle MR, Goggi JL, Allen L, Barnett J, Morrison MS. Battle MR, et al. J Nucl Med. 2011 Mar;52(3):424-30. doi: 10.2967/jnumed.110.077479. Epub 2011 Feb 14. J Nucl Med. 2011. PMID: 21321268 Free article.

3

[¹⁸F]fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αvβ 3 and α vβ 5 integrins.

Mena E, Owenius R, Turkbey B, Sherry R, Bratslavsky G, Macholl S, Miller MP, Somer EJ, Lindenberg L, Adler S, Shih J, Choyke P, Kurdziel K. Mena E, et al. Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1879-88. doi: 10.1007/s00259-014-2791-x. Epub 2014 Jun 28. Eur J Nucl Med Mol Imaging. 2014. PMID: 24973039 Free PMC article.

4

In vivo alpha-V beta-3 integrin expression in human aortic atherosclerosis.

Jenkins WS, Vesey AT, Vickers A, Neale A, Moles C, Connell M, Joshi NV, Lucatelli C, Fletcher AM, Spratt JC, Mirsadraee S, van Beek EJ, Rudd JH, Newby DE, Dweck MR. Jenkins WS, et al. Heart. 2019 Dec;105(24):1868-1875. doi: 10.1136/heartjnl-2019-315103. Epub 2019 Aug 17. Heart. 2019. PMID: 31422361 Free PMC article.

5

Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.

Kramer GM, Frings V, Hoetjes N, Hoekstra OS, Smit EF, de Langen AJ, Boellaard R. Kramer GM, et al. J Nucl Med. 2016 Sep;57(9):1343-9. doi: 10.2967/jnumed.115.170225. Epub 2016 Apr 21. J Nucl Med. 2016. PMID: 27103020 Free article.

6

Test-Retest Variability in Lesion SUV and Lesion SUR in ¹⁸F-FDG PET: An Analysis of Data from Two Prospective Multicenter Trials.

Hofheinz F, Apostolova I, Oehme L, Kotzerke J, van den Hoff J. Hofheinz F, et al. J Nucl Med. 2017 Nov;58(11):1770-1775. doi: 10.2967/jnumed.117.190736. Epub 2017 May 4. J Nucl Med. 2017. PMID: 28473598 Free PMC article.

7

[¹⁸F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer.

Sharma R, Valls PO, Inglese M, Dubash S, Chen M, Gabra H, Montes A, Challapalli A, Arshad M, Tharakan G, Chambers E, Cole T, Lozano-Kuehne JP, Barwick TD, Aboagye EO. Sharma R, et al. Eur J Nucl Med Mol Imaging. 2020 May;47(5):1239-1251. doi: 10.1007/s00259-019-04532-z. Epub 2019 Nov 21. Eur J Nucl Med Mol Imaging. 2020. PMID: 31754793 Free PMC article. Clinical Trial.

8

Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials.

Weber WA, Gatsonis CA, Mozley PD, Hanna LG, Shields AF, Aberle DR, Govindan R, Torigian DA, Karp JS, Yu JQ, Subramaniam RM, Halvorsen RA, Siegel BA; ACRIN 6678 Research team; MK-0646-008 Research team. Weber WA, et al. J Nucl Med. 2015 Aug;56(8):1137-43. doi: 10.2967/jnumed.114.147728. Epub 2015 Apr 23. J Nucl Med. 2015. PMID: 25908829 Free PMC article. Clinical Trial.

9

Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.

Schmidt H, Brendle C, Schraml C, Martirosian P, Bezrukov I, Hetzel J, Müller M, Sauter A, Claussen CD, Pfannenberg C, Schwenzer NF. Schmidt H, et al. Invest Radiol. 2013 May;48(5):247-55. doi: 10.1097/RLI.0b013e31828d56a1. Invest Radiol. 2013. PMID: 23519008

10

Preliminary clinical assessment of the relationship between tumor alphavbeta3 integrin and perfusion in patients studied with [(18)F]fluciclatide kinetics and [ (15)O]H 2O PET.

Kenny LM, Tomasi G, Turkheimer F, Larkin J, Gore M, Brock CS, Mangar S, Aboagye EO. Kenny LM, et al. EJNMMI Res. 2014 Dec;4(1):30. doi: 10.1186/s13550-014-0030-x. Epub 2014 Aug 8. EJNMMI Res. 2014. PMID: 26055935 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year